Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | AOC1 | P19801 | 2/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882798 | 0.82 | IAPP (0.38) | ELANEGABRA1GABRB2 | |
| SCHEMBL10037111 | 0.78 | ELANE (0.45) | ELANEGABRA1GABRB2TDP1SCN5A | |
| SCHEMBL13689141 | 0.73 | ADRA2B (0.42) | TDP1AOC1AOC3ALDH1A1LMNA | |
| SCHEMBL8077425 | 0.73 | TYR (0.45) | ELANETDP1 | |
| SCHEMBL2548811 | 0.70 | TYR (0.39) | TDP1 | |
| SCHEMBL30358479 | 0.70 | KCNH2 (0.38) | GABRA1GABRB2GRM5SCN5ACACNA1C | |
| SCHEMBL11663834 | 0.69 | MAPT (0.39) | GRM5SCN5AKCNH2ALDH1A1LMNA | |
| SCHEMBL13601937 | 0.69 | GRM5 (0.51) | TDP1GRM5ALDH1A1LMNA | |
| SCHEMBL10705279 | 0.68 | ALDH1A1 (0.45) | ALDH1A1LMNA | |
| SCHEMBL6885297 | 0.68 | IAPP (0.36) | ELANEGABRA1GABRB2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552990-B1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-04-19 | — | — | EP | claimed |
| EP-2552990-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | Dow Global Technologies LLC (US) | 2013-02-06 | — | — | EP | claimed |
| US-20130018147-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-01-17 | — | — | US | claimed |
| WO-2011123241-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-10-06 | — | — | WO | claimed |
| EP-2552990-B1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2552990-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | Dow Global Technologies LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20130018147-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-8212078-B2 | Making chain extenders with slower cure rates; reacting a ketone and/or aldehyde with a primary amine in the presence of an acidic ion exchange resin and hydrogenation agent; making diimine same way but excluding hydrogenation agent; e.g. N,N'-di-5-nonyl-isophoronediamine | ALBEMARLE CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2011123241-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-10-06 | — | — | WO | disclosed |
| US-7767858-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2143707-A2 | Secondary diamine | Albermarle Corporation (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080315155-A1 | Diamines Having Reduced Color | ALBEMARLE CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1868987-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7288677-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2007079365-A2 | BLENDS OF DIAMINES HAVING REDUCED COLOR | ALBEMARLE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079367-A1 | DIAMINES HAVING REDUCED COLOR | ALBEMARLE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006104528-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | ELANE 3408/4885GABRA1 2453/4885GABRB2 2408/4885 |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | ELANE 3408/4885GABRA1 2453/4885GABRB2 2408/4885 |
| US-20080315155-A1 | Diamines Having Reduced Color | DDT, DPYD, DDC | ELANE 3624/4885GABRA1 2356/4885GABRB2 2092/4885 |
| US-20060217567-A1 | Diimines and secondary diamines | DDT, DDC, AOC1 | ELANE 3408/4885GABRA1 2453/4885GABRB2 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.